Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats

Diabetes, Obesity and Metabolism

Volumn 13, Issue 5, 2011, Pages 408-417

  Nadkarni, P P ^a   Costanzo, R M ^a   Sakagami, M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Animal pharmacology; Antiobesity drug; Appetite control; Experimental pharmacology; Obesity therapy; Pharmacokinetics

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; NEUROPEPTIDE Y; PEPTIDE YY; PEPTIDE YY [13-36]; PEPTIDE YY [3-36]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARCUATE NUCLEUS; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; BODY WEIGHT; BRAIN; CONTROLLED STUDY; FOOD INTAKE; HALF LIFE TIME; HYPOTHALAMUS; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MONITORING; NONHUMAN; ONCOGENE C FOS; RAT; SINGLE DRUG DOSE;

EID: 79953044653     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01363.x     Document Type: Article

References (44)

1. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): part I. distribution, release and actions. Obes Surg 2006; 16: 651-658.
2. le Roux CW, Bloom SR. Peptide YY, appetite and food intake. Proc Nutr Soc 2005; 64: 213-216.
3. Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite regulation and obesity. J Physiol 2009; 587: 19-25.
4. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002; 418: 650-654.
5. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.
6. Pittner RA, Moore CX, Bhavsar SP et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004; 28: 963-971.
7. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 2005; 146: 879-888.
8. Degen L, Oesch S, Casanova M et al. Effect of peptide YY3336 on food intake in humans. Gastroenterology 2005; 129: 1430-1436.
9. Unniappan S, McIntosh CHS, Demuth H-U, Heiser U, Wolf R, Kieffer TJ. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia 2006; 49: 1915-1923.
10. Chelikani PK, Haver AC, Reeve JR Jr, Keire DA, Reidelberger RD. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 2006; 290: R295-R305.
11. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 2007; 293: E604-E609.
12. Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol 2008; 59: 55-92.
13. 34]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 2000; 279: G126-G131.
14. Broberger C, Landry M, Wong H, Walsh JN, Hökfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997; 66: 393-408.
15. Abbott CR, Small CJ, Kennedy AR et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 2005; 1043: 139-144.
16. Koda S, Date Y, Murakami N et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 2005; 146: 2369-2375.
17. Abbott CR, Monteiro M, Small CJ et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005; 1044: 127-131.
18. Halatchev IG, Cone RD. Peripheral administration of PYY3-36 produces conditioned taste aversion in mice. Cell Metab 2005; 1: 159-168.
19. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146: 3748-3756.
20. 125I] hPP) in the CNS: enrichment in the area postrema. J Mol Neurosci 2007; 33: 294-304.
21. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58: 996-1008.
22. Tschöp M, Castañeda TR, Joost HG et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 2004; 430: 1-4.
23. Gantz I, Erondu N, Mallick M et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007; 92: 1754-1757.
24. Khafagy El-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007; 59: 1521-1546.
25. Wahlestedt C, Yanaihara N, Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept 1986; 13: 307-318.
26. 125I-peptide YY bind to multiple receptor sites in rat brain. Mol Pharmacol 1988; 34: 779-792.
27. Westfall TC, Naes L, Gardner A, Yang C-L. Neuropeptide Y induced attenuation of catecholamine synthesis in the rat mesenteric arterial bed. J Cardiovasc Pharmacol 2006; 47: 723-728.
28. Abbott CR, Small CJ, Sajedi A et al. The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat. Int J Obes (Lond) 2006; 30: 288-292.
29. Farley C, Cook JA, Spar BD, Austin TM, Kowalski TJ. Meal pattern analysis of diet-induced obesity in susceptible and resistant rats. Obes Res 2003; 11: 845-851.
30. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
31. Kruger L, Saporta S, Swanson LW. Photographic Atlas of the Rat Brain. Cambridge: Cambridge University Press, 1995.
32. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7: 49-75.
33. van den Hoek AM, Heijboer AC, Voshol PJ et al. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab 2007; 292: E238-E245.
34. Guo Y, Ma L, Enriori PJ et al. Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring) 2006; 14: 1562-1570.
35. Batterham RL, Heffron H, Kapoor S et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4: 223-233.
36. Reidelberger RD, Haver AC, Chelikani PK, Buescher JL. Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R449-R458.
37. Roth JD, Coffey T, Jodka CM et al. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 2007; 148: 6054-6061.
38. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001; 74: 683-701.
39. Chelikani PK, Haver AC, Reidelberger RD. Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1064-R1070.
40. Grandt D, Schimiczek M, Beglinger C et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 1994; 51: 151-159.
41. Kera Y, Liu Z, Matsumoto T, Sorimachi Y, Nagasaki H, Yamada R. Rat and human membrane dipeptidase: tissue distribution and developmental changes. Comp Biochem Physiol B Biochem Mol Biol 1999; 123: 53-58.
42. van der Velden VHJ, Hulsmann AR. Peptidases: structure, function and modulation of peptide-mediated effects in the human lung. Clin Exp Allergy 1999; 29: 445-456.
43. Jin H, Cai L, Lee K et al. A physiological role of peptide YY on exocrine pancreatic secretion in rats. Gastroenterology 1993; 105: 208-215.
44. Chelikani PK, Haver AC, Reidelberger RD. Dose-dependent effects of peptide YY(3-36) on conditioned taste aversion in rats. Peptides 2006; 27: 3193-3201.